FEMY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.14M

+96.02%

-0.090

-60.87%

2.07M

+506.58%

-0.090

-60.87%

2.16M

+427.77%

-0.080

-50%

Estimates Revision

The market is revising Downward the revenue expectations for Femasys Inc. (FEMY) for FY2025, with the revenue forecasts being adjusted by -29.2% over the past three months. During the same period, the stock price has changed by -9.03%.

Revenue Estimates for FY2025

Revise Downward

-29.2%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-6.14%

In Past 3 Month

Stock Price

Go Down

-9.03%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

5.50

High

8.00

Current: 0.000

Low

3.00

Averages

5.50

High

8.00

Laidlaw

Yale Jen

initiated

$6.50

2025-11-20

Reason

Laidlaw

Yale Jen

Price Target

$6.50

2025-11-20

initiated

Reason

Laidlaw analyst Yale Jen initiated coverage of Femasys with a Buy rating and $6.50 price target. Femasys is a development stage medical technology company focusing on two lead women healthcare products, FemaSeed and FemBloc, the analyst tells investors in a research note. The firm says FemaSeed is exploring a new and large market opportunity via gynecologist channel while FemBloc is heading to pivotal clinical study backed by "robust" prior clinical data.

JonesResearch

Buy

downgrade

$10 -> $6

2025-05-13

Reason

JonesResearch

Price Target

$10 -> $6

2025-05-13

downgrade

Buy

Reason

JonesResearch lowered the firm's price target on Femasys to $6 from $10 and keeps a Buy rating on the shares. The company reported Q1 earnings with no major updates to catalysts or its cash runway, the analyst tells investors in a research note. The firm remains positive on Femasys, but cut its price target to reflect the delayed launch of FemaSeed and an increase in share count from potential financing in 2025.

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$15

2025-03-28

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$15

2025-03-28

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Maintains

$12 → $15

2025-03-19

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$12 → $15

2025-03-19

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$12

2025-03-18

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$12

2025-03-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$12

2025-03-13

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$12

2025-03-13

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Femasys Inc (FEMY.O) is -1.82, compared to its 5-year average forward P/E of -2.19. For a more detailed relative valuation and DCF analysis to assess Femasys Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.19

Current PE

-1.82

Overvalued PE

-0.57

Undervalued PE

-3.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

14.39

Current PS

4.82

Overvalued PS

32.88

Undervalued PS

-4.10

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

FEMY News & Events

Events Timeline

No data

News

2.0

01-06NASDAQ.COM

Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement

9.5

2025-12-24Benzinga

Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025

9.0

2025-12-20NASDAQ.COM

Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO

People Also Watch

Frequently Asked Questions

What is Femasys Inc (FEMY) stock price today?

The current price of FEMY is 0.5905 USD — it has increased 0 % in the last trading day.

What is Femasys Inc (FEMY)'s business?

Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.

What is the price predicton of FEMY Stock?

What is Femasys Inc (FEMY)'s revenue for the last quarter?

Femasys Inc revenue for the last quarter amounts to 729.39K USD, increased 31.44 % YoY.

What is Femasys Inc (FEMY)'s earnings per share (EPS) for the last quarter?

Femasys Inc. EPS for the last quarter amounts to -0.10 USD, decreased -58.33 % YoY.

What changes have occurred in the market's expectations for Femasys Inc (FEMY)'s fundamentals?

How many employees does Femasys Inc (FEMY). have?

Femasys Inc (FEMY) has 69 emplpoyees as of January 09 2026.

What is Femasys Inc (FEMY) market cap?

Today FEMY has the market capitalization of 35.14M USD.